Werewolf Therapeutics (HOWL) Projected to Post Earnings on Thursday

Werewolf Therapeutics (NASDAQ:HOWL) will likely be announcing its earnings results before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.43) per share for the quarter.

Werewolf Therapeutics Trading Up 2.6 %

Shares of HOWL opened at $1.17 on Wednesday. The business has a 50-day moving average of $1.40 and a 200 day moving average of $1.86. Werewolf Therapeutics has a fifty-two week low of $1.03 and a fifty-two week high of $7.17. The firm has a market cap of $52.14 million, a P/E ratio of -0.76 and a beta of 0.36. The company has a debt-to-equity ratio of 0.29, a quick ratio of 10.10 and a current ratio of 10.10.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on HOWL shares. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Werewolf Therapeutics in a report on Tuesday, November 19th. JMP Securities decreased their price objective on Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating for the company in a report on Tuesday, January 14th.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.